46
Participants
Start Date
June 4, 2015
Primary Completion Date
April 14, 2022
Study Completion Date
April 14, 2022
Carboplatin
Carboplatin AUC 6 IV, D1 for 4 cycles (cycle = 21 days)
Nab-paclitaxel
Nab-paclitaxel 100 mg/m2 IV, D1, D8, D15 for 4 cycles (cycle = 21 days)
MK-3475 (Phase I)
"MK-3475 2 mg/kg IV, D1 for 4 cycles (Cohort 1) or 3 cycles (Cohort 2) (cycle = 21 days)~Maintenance MK-3475 2 mg/kg IV continues every 21 days after Cycle 4 for up to 2 years."
MK-3475 (Phase II)
"MK-3475 200 mg IV Day 1 of each cycle (cycle = 21 days)~Maintenance MK-3475 2 mg/kg IV continues every 21 days after Cycle 4 for up to 2 years."
University of Virginia Cancer Center, Charlottesville
Indiana University Melvin and Bren Simon Cancer Center, Indianapolis
IU Health Central Indiana Cancer Center, Indianapolis
Northwestern University, Robert H. Lurie Comprehensive Cancer Center, Chicago
City of Hope, Duarte
Collaborators (2)
Hoosier Cancer Research Network
OTHER
Merck Sharp & Dohme LLC
INDUSTRY
Celgene Corporation
INDUSTRY
Nisha Mohindra, MD
OTHER